Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Erik %C5%A0kof) .

11 - 20 / 99
Na začetekNa prejšnjo stran12345678910Na naslednjo stranNa konec
11.
Phase II study of fluorouracil, leucovorin and interferon alpha-2a in patients with advanced colon cancer
Borut Štabuc, Aleksandra Markovič, Erik Brecelj, Samir Bešlija, Tomaž-Edvard Cizej, 1998, izvirni znanstveni članek

Povzetek: Based on in viro studies that have demonstrated synergy between fluorouracil (5-FU) and leucovorin (LV) as well as between 5-FU and recombinant alpha-2a interferon (IFN) against colon cancer cell lines a phase II study was carried out to evaluate the toxicity and clinical activity of 5-FU modulated with LV and IFN in patients with metastatic colon cancer. Twenty-two chemotherapy naive patients with measurable metastases of colon cancer have been treated with daily doses of 5-FU 600 mg/m2 in 6-hr intravenous infusion, and of LV 20 mg/m2 intravenously and IFN 6 MU subcutaneously, for 5 days every 4 weeks. Median age was 60 years, median PS (ECOG) was 1 (range 0-2). Liver, soft tissue and lung metastases were found in 12, 5 and 8 patients, respectively. Nineteen patients had a single metastatic site, two double, whereas one had more than two metastatic sites. Patients had 2-9 (mean 5) cycles of treatment.Objective response was observed in 7 patients (32%), and stable disease in 7 patients (32%). Overall median survival was 12.5 months, and for responders 14.4 months. Responses were generally short and median time for progression was 5.5 months. The most frequent adverse reactions were flu-like syndrome (50%), nausea/vomiting (36%), diarhoea (13Č), stomatitis (27%) and leucopenia (13%). This regimen of 5-FU with LV and IFN administration does notappear to be superior to previously published shedules of 5-FU with IFN or 5-FU with LV.
Objavljeno v DiRROS: 19.01.2024; Ogledov: 164; Prenosov: 45
.pdf Celotno besedilo (430,62 KB)

12.
13.
Experimental investigation of the axial strength of glued-in rods in cross laminated timber
Boris Azinović, Erik Serrano, Miha Kramar, Tomaž Pazlar, 2018, izvirni znanstveni članek

Povzetek: This paper presents results from an experimental assessment of glued-in rods in cross laminated timber (CLT). For the purposes of the study more than 60 pull-pull tests were performed, where the specimens varied in terms of bonded-in length (from 80 to 400 mm), rod diameter (16-24 mm) and rod-to-grain angle (parallel and perpendicular). Several different failure modes that are not common for other applications of glued-in rods (e.g., a failure between CLT layers) were obtained for the analysed CLT specimens. It was found that these failure mechanisms can substantially influence the obtained ultimate tension loads. At the end, the experimental results were compared with empirical and semi-empirical equations for estimating the pull-out strength of glued-in rods in structural timber and glulam. The comparison showed that most of the existing equations overestimate the ultimate tension loads for specimens with the rod parallel to the grain and underestimate the ultimate tension load for specimens with the rod perpendicular to the grain. The results vary because the possible CLT failure modes were not included in previous studies. Further studies are proposed to improve the equations for glued-in rods in CLT.
Ključne besede: glued-in rods, cross laminated timber (CLT), pull-pull experiment, glued-in length, rod-to-grain angle, failure mechanisms in CLT
Objavljeno v DiRROS: 29.11.2023; Ogledov: 214; Prenosov: 175
.pdf Celotno besedilo (4,13 MB)
Gradivo ima več datotek! Več...

14.
Naše izkušnje s PARP inhibitorji pri raku jajčnikov na OI Ljubljana
Erik Škof, 2023, objavljeni znanstveni prispevek na konferenci

Ključne besede: rak jajčnikov, sistemsko zdravljenje, ginekološki raki
Objavljeno v DiRROS: 23.11.2023; Ogledov: 207; Prenosov: 115
.pdf Celotno besedilo (340,15 KB)
Gradivo ima več datotek! Več...

15.
16.
Glued-in rods in cross laminated timber - numerical simulations and parametric studies
Boris Azinović, Henrik Danielsson, Erik Serrano, Miha Kramar, 2019, izvirni znanstveni članek

Povzetek: Numerical simulations and parametric studies of glued-in rods in cross-laminated timber have been performed. The simulations were based on 3D finite element analysis, using a cohesive surface model for the bond-lines between the laminations and the bond-line along the rod. The parametric studies investigated the influence of the glued-in length, the rod diameter, and the rod-to-grain angle on the load-bearing capacity and stiffness of the connection. The analyses showed that the load-bearing capacity generally increases with the glued-in length and the rod diameter, which agrees well with experiments. For different rod-to-grain angles, different mechanical behaviour was observed, especially considering the failure modes.
Ključne besede: glued-in rods, cross laminated timber (CLT), parametric study, nonlinear numerical modelling, glued-in length, rod diameter, rod orientation
Objavljeno v DiRROS: 13.09.2023; Ogledov: 236; Prenosov: 144
.pdf Celotno besedilo (2,66 MB)
Gradivo ima več datotek! Več...

17.
Imunoterapija pri raku telesa maternice
Erik Škof, 2023, objavljeni znanstveni prispevek na konferenci

Povzetek: Nova molekularna klasifikacija raka telesa maternice je omogočila novo, usmerjeno zdravljenje bolnic z rakom telesa maternice. Glavno novost predstavlja imunoterapija z zaviralci imunskih nadzornih točk (zaviralci PD-1) pri bolnicah z metastatskim rakom telesa maternice v 2. liniji zdravljenja, po predhodnem zdravljenu s kemoterapijo. Evropska agencija za zdravila (EMA) je odobrila uporabo dveh zaviralcev PD-1 receptorjev - dostarlimab in pembrolizumab v monoterapiji v primeru, da gre za okvaro MMR proteinov v tumorju (dMMR/MSI-H karcinom). Odobrena je tudi kombinacija pembrolizumaba in lenvatiniba (zaviralec tirozin kinaz) v 2. liniji zdravljenja metastatske bolezni, po predhodnem zdravljenju s kemoterapijo, ne glede na status MMR proteinov, torej tudi v primeru, da ne gre za okvaro MMR proteinov v tumorju (pMMR/MSS karcinom). Pred kratkim so bili objavljeni rezultati, ki kažejo učinkovitost pembrolizumaba in dostarlimaba v kombinaciji s kemoterapijo v 1. liniji napredovale ali metastatske bolezni. V adjuvantnem zdravljenju zaenkrat še nimamo podatkov o učinkovitosti imunoterapije - potekajo klinične raziskave.
Ključne besede: rak maternice, ginekološki raki, ginekološka onkologija
Objavljeno v DiRROS: 30.05.2023; Ogledov: 323; Prenosov: 126
.pdf Celotno besedilo (281,13 KB)
Gradivo ima več datotek! Več...

18.
Značilnosti rastlinstva, živalstva in gozdnih sestojev v povodju Liščaka v južnih Julijskih Alpah
Peter Razpet, Karin Rutar, Erik Kragelj, Igor Dakskobler, 2023, izvirni znanstveni članek

Povzetek: Članek vsebuje opis značilnosti rastlinstva in živalstva odmaknjene, le po stezah dostopne in skoraj povsem gozdnate grape v zahodni Sloveniji. Raznolikost gozdnih združb in sestojev je povezana z naravnimi značilnostmi, karbonatno-silikatno geološko podlago in velikimi strminami, a tudi s pozno poselitvijo in popolnim izumrtjem zaselkov pred petdesetimi leti in več. Bukovi sestoji, ki so jih nekoč zelo sekali, se že dolgo razvijajo po naravnih zakonitostih, nanje koreniteje vplivajo predvsem vetrolomi in žled. Pionirska grmišča in gozdovi so raznoliki po zgradbi in vrstni sestavi. V bližini nekdanjih bivališč so mogočna stara drevesa, gorski bresti, veliki jeseni in smreke, na nekdanjih njivah nastaja orehov gozd. Grapa je naravna vrednota; predlagamo, naj bi bilo celotno njeno povodje.
Ključne besede: rastlinstvo, živalstvo, drugotna sukcesija, gozdna krajina, Baška dolina, Slovenija
Objavljeno v DiRROS: 19.05.2023; Ogledov: 353; Prenosov: 99
.pdf Celotno besedilo (964,91 KB)

19.
Napovedna vrednost izraženosti androgenskega receptorja za razsoj v kosti pri trojno negativnem raku dojk
Petra Ilenič, Ajda Herman, Erik Langerholc, Barbara Gazić, Boštjan Šeruga, 2022, objavljeni povzetek strokovnega prispevka na konferenci

Ključne besede: onkologija, rak dojke, kemoterapija
Objavljeno v DiRROS: 27.01.2023; Ogledov: 328; Prenosov: 96
.pdf Celotno besedilo (47,32 KB)

20.
Iskanje izvedeno v 0.26 sek.
Na vrh